Silexion Therapeutics Corp is a IL-based company operating in Biotechnology industry. Silexion Therapeutics Corp is an Israel-based oncology-focused biotechnology company. The firm is engaged in development of treatments for unsatisfactorily treated solid tumor cancers, which have the mutated KRAS oncogene. The KRAS gene is an oncogene that is involved in regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based on its research of refractory solid tumor cancers, it is developing a platform focused on the silencing of the KRAS oncogene using ribonucleic acid (RNA)-interference therapeutics. Its lead product candidate, SIL-204B, consists of locally administered small interfering RNAs (siRNA), in an extended-release formulation, as a preferred treatment of locally advanced pancreatic cancer patients, in combination with standard-of-care chemotherapy. Its clinical-stage pipeline is focused on treatment for pancreatic cancer (PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected.
Follow-Up Questions
¿Qué tal es el rendimiento del precio de la acción SLXN?
El precio actual de SLXN es de $3.73, ha increased un 3.35% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Silexion Therapeutics Corp?
Silexion Therapeutics Corp pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de Silexion Therapeutics Corp?
La capitalización bursátil actual de Silexion Therapeutics Corp es $3.9M
¿Es Silexion Therapeutics Corp una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 3 analistas han realizado calificaciones de análisis para Silexion Therapeutics Corp, incluyendo 2 fuerte compra, 4 compra, 1 mantener, 0 venta, y 2 fuerte venta
